Free Newsletter
Medicare covers Avastin here, but not there
In another U.S. meets the U.K. story, a Colorado state representative is fighting the feds to get Roche/Genentech's Avastin covered by Medicare. Yes, Medicare. Apparently, the Center for Medicare and Medicaid Services doesn't cover Avastin treatment for ovarian cancer in Colorado, despite the fact that it's paid for in California and New York.
"How can I help you effect this change in policy, quickly, before one more Colorado woman died from ovarian cancer by dint of being on the wrong side of a state border?" she wrote (as quoted by the Denver Post). Shades of the U.K.'s National Health Service! And you thought that kind of rationing only happened overseas.
Apparently, what's happened in Colorado is that the state's Medicare contractor has chosen not to pay for the drug. And that's perfectly OK under federal rules, because a.) the FDA hasn't approved Avastin for ovarian cancer, though it can be used off-label for that purpose, and b.) the Centers for Medicare hasn't ruled one way or another on Avastin in ovarian cancer. That gives individual regions the power to make their own decisions about off-label coverage.
- see the Denver Post story
- check out the background, also in the Denver Post
Related Articles:
Next up in reform debate: Medicare rebates
Medicare: Right to restrict anemia meds
MedPAC: Are new drugs worth higher prices?
Medicare to crack down on PBM 'lock-in'
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: